Skip to main content
Contact Us
Subscribe
E-Edition
44°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Merck & Co., Inc.
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Merck to Participate in the Citi 2024 Global Healthcare Conference
November 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
November 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
November 22, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 22, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
November 22, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Surendralal Karsanbhai Elected to Merck Board of Directors
November 22, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
November 21, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces First-Quarter 2025 Dividend
November 19, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
November 19, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
November 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Jefferies London Healthcare Conference
November 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
November 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial
November 12, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024
November 12, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the UBS Global Healthcare Conference
November 06, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Third-Quarter 2024 Financial Results
October 31, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
October 28, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
MRNA
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
October 24, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older
October 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
October 17, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
October 16, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
October 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
October 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
October 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
October 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
September 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
September 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
September 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
September 24, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
September 20, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.